Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Asahi Kasei will unveil its AKXY2 concept car at K 2022 in Düsseldorf, Germany, from October 19-26. This model showcases the company's advanced technology and sustainable materials, including innovative particle foams and bio-based fillers aimed at electric vehicles. Key materials on display include polycarbonates produced using CO2 as a raw material and premium microfiber Dinamica®. The AKXY2 also features cellulose-based materials and next-gen engineering plastics. Asahi Kasei emphasizes its commitment to sustainability and innovation across its diverse product portfolio.
Asahi Kasei Bioprocess America will showcase its MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt, scheduled from August 22-26, 2022. This innovative system blends buffers from concentrates in small, single-use bags, significantly enhancing efficiency and precision in pharmaceutical production. It has received multiple accolades, including ‘Best in Show’ at Interphex 2017 and ‘Technology of the Decade’ from Bioprocess International in 2012. The system supports rapid and sustainable pharmaceutical manufacturing, allowing medicines to reach patients globally faster.
Summary not available.
Asahi Kasei has developed a new system for calculating the carbon footprint (CFP) of its synthetic rubber and elastomers products, which will start providing data to customers from June 2022. The system utilizes the DEEP group-wide management infrastructure for enhanced CFP visualization and reduction strategies. Asahi Kasei aims for carbon neutrality by 2050, incorporating sustainable practices like using butadiene derived from plastic waste. This system is crucial as regulations on carbon footprints increase, and it tailors data to meet customer requirements.
Asahi Kasei has developed a new platform in collaboration with NTT DATA to monitor greenhouse gas (GHG) emissions and calculate carbon footprints for its performance plastics used in various industries. This initiative, part of its sustainability efforts, began in April 2022, with customer data sharing starting in May 2022. The platform aims to provide detailed insights into GHG emissions across the supply chain, enhancing accountability and supporting decarbonization. Asahi Kasei remains committed to achieving carbon neutrality by 2050.
Asahi Kasei Medical announced on April 14, 2022, the acquisition of Bionova Scientific, LLC, specializing in biopharmaceutical contract development and manufacturing. This strategic move enhances Asahi Kasei's bioprocess business, allowing it to offer advanced manufacturing capabilities for next-generation antibody drugs. Bionova's GMP-compliant facility and expertise in complex biopharmaceuticals are set to meet increasing market demand. The acquisition is pending necessary regulatory approvals.
Summary not available.
Asahi Kasei will showcase its AKXY Pod automotive interior prototype at the SAE World Congress Experience in Detroit from April 5-7, 2022. The presentation includes advancements in keeping vehicle cabins safe from pathogens using Crystal IS's Klaran UVC LEDs. The Healthy Car Portfolio emphasizes safety through technologies like touch-free alcohol sensors and innovative textiles. The event will highlight solutions for enhancing comfort and cleanliness in vehicles while addressing post-COVID-19 market needs, emphasizing the importance of healthy automotive innovations.
Asahi Kasei has announced a strategic partnership with Genomatica to develop biomass-derived hexamethylenediamine (HMD), enhancing the production of sustainable polyamide 66 (Leona™). This collaboration allows Asahi Kasei to evaluate bio-HMD as a feedstock, aiming to be first-to-market in sustainable engineering plastics for automotive and electronics. Asahi Kasei targets carbon neutrality by 2050, with bio-HMD potentially reducing greenhouse gas emissions. The partnership aligns with increasing global demand for eco-friendly materials in manufacturing.
Asahi Kasei Medical plans to expand its production capacity for Planova™ filters by constructing a new assembly plant in Nobeoka, Miyazaki, Japan. This facility aims to enhance manufacturing automation and efficiency, with construction set to begin in Q3 2022 and completion expected in early 2024. The demand for Planova™ filters has surged due to the COVID-19 pandemic's impact on the biotherapeutics market. Asahi Kasei Medical has been investing in production capacity to meet this demand, reinforcing its position as a market leader in virus filtration.